Elicio Therapeutics, Inc. (ELTX)

Pharmaceutical Preparations · market cap $49M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Elicio Therapeutics (ELTX) is a 32-person clinical-stage biotech with a $63M market cap advancing ELI-002 7P through Phase 2 for pancreatic ductal adenocarcinoma (PDAC). The company holds $14.9M in cash representing roughly 3.9 months of runway, creating acute near-term financing pressure. No recent clinical catalysts have been disclosed; the next scheduled event is an August 6, 2026 earnings release.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ELI-002 7P	Phase 2	Pancreatic Ductal Adenocarcinoma

Price & technical context

3-month

-40.4%

6-month

-82.0%

12-month

-82.4%

52-wk range

$1.77–$14.85

vs 50-day MA

-25.9%

vs 200-day MA

-74.2%

Realized vol

173.4%

Max drawdown

-88.1%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ELTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.